Loading clinical trials...
Loading clinical trials...
Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Triptolide was shown in experimental studies to inhibit the cyst formation and growth in ADPKD models, while triptolide-containing formulation was revealed to potentially slow the disease progression in several proteinuric ADPKD patients in our clinical practice. It remains to be shown the effect of triptolide-containing formulation on total kidney volume (TKV) enlargement and renal function protection in ADPKD patients.
Randomized Controlled Trial
Age
40 - 75 years
Sex
ALL
Healthy Volunteers
No
Shanghai Changzheng Hospital
Shanghai, Shanghai Municipality, China
Start Date
April 1, 2014
Primary Completion Date
May 1, 2016
Completion Date
May 1, 2016
Last Updated
April 17, 2014
100
ESTIMATED participants
Triptolide-Containing Formulation
DRUG
Placebo
DRUG
Lead Sponsor
Shanghai Changzheng Hospital
NCT07454174
NCT06594367
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06289998